



(12) Translation of
European patent specification

(11) NO/EP 3251699 B1

NORWAY

(19) NO

(51) Int Cl.

A61K 31/445 (2006.01)

A61P 3/04 (2006.01)

A61K 9/20 (2006.01)

A61P 17/02 (2006.01)

A61K 9/48 (2006.01)

A61P 17/14 (2006.01)

A61K 31/4178 (2006.01)

A61P 25/00 (2006.01)

A61K 31/4458 (2006.01)

A61P 25/14 (2006.01)

A61K 31/48 (2006.01)

A61P 25/30 (2006.01)

A61K 31/517 (2006.01)

A61P 25/32 (2006.01)

A61K 45/06 (2006.01)

A61P 25/36 (2006.01)

A61K 48/00 (2006.01)

A61P 43/00 (2006.01)

A61P 1/14 (2006.01)

Norwegian Industrial Property Office

(45) Translation Published 2024.07.01

(80) Date of The European
Patent Office Publication of
the Granted Patent 2024.04.17

(86) European Application Nr. 16743696.3

(86) European Filing Date 2016.01.28

(87) The European Application's
Publication Date 2017.12.06

(30) Priority 2015.01.28, US, 201562108616 P

(84) Designated Contracting
States: AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ;
IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ;
SK ; SM ; TR

(73) Proprietor Duke University, 2812 Erwin Road, Suite 306 P.O. Box 90083, Durham, North
Carolina 27705, USA

(72) Inventor LEE, Tong Hyon, 115 Stratford Dr., Chapel Hill, North Carolina 27516, USA

(74) Agent or Attorney BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54) Title **COMPOSITION COMPRISING METHYLPHENIDATE AND ONDANSETRON FOR USE IN
SUBSTANCE-RELATED DISORDERS**

(56) References
Cited: US-A- 6 113 879
US-A1- 2013 116 215
LEE, T. H. ET AL.: 'Pharmacologically-mediated Reactivation and Reconsolidation Blockade of
the Psychostimulant-abuse Circuit: A Novel Treatment Strategy.' DRUG & ALCOHOL
DEPENDENCE vol. 124, 2012, pages 11 - 18, XP028520041
GRADY, T. A. ET AL.: 'Biological and Behavioral Responses to D-amphetamine, Alone and in
Combination with the Serotonin 3 Receptor Antagonist Ondansetron' HEALTHY VOLUNTEERS.
PSYCHIATRY RESEARCH vol. 64, 1996, pages 1 - 10, XP055321105
Anonymous: "PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and
Immediate-Release Methylphenidate (Ritalin)(OND003IND) - Tabular View - ClinicalTrials.gov",
, 21 June 2011 (2011-06-21), pages 1-10, XP055486313, Internet Retrieved from the Internet:

URL:<https://clinicaltrials.gov/ct2/show/record/NCT01377662> [retrieved on 2018-06-20]
SZABO STEVEN T ET AL: "284: Translational Development of Novel Pharmacotherapeutic Strategies for Psychostimulant Dependence", BIOLOGICAL PSYCHIATRY; 65TH ANNUAL CONVENTION OF THE SOCIETY-OF-BIOLOGICAL-PSYCHIATRY, ELSEVIER SCIENCE, NEW YORK, NY; US; NEW ORLEANS, LA, USA, vol. 67, no. 9, Suppl. S, 1 May 2010 (2010-05-01), page 88S, XP009506282, ISSN: 0006-3223, DOI: 10.1016/J.BIOPSYCH.2010.03.007 [retrieved on 2010-04-08]
TONG H LEE ET AL: "Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: A novel treatment strategy", DRUG AND ALCOHOL DEPENDENCE, ELSEVIER SCIENTIFIC PUBLISHERS, IR, vol. 124, no. 1, 27 January 2012 (2012-01-27), pages 11-18, XP028520041, ISSN: 0376-8716, DOI: 10.1016/J.DRUGALCDEP.2012.01.021 [retrieved on 2012-02-02]
BHATIA, K. S. ET AL.: 'Reversal of Long-term Methamphetamine Sensitization by Combination of Pergolide with Ondansetron or Ketanserin, but not Mirtazapine.' BEHAVIOURAL BRAIN RESEARCH vol. 223, 2011, pages 227 - 232, XP028228514

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. En enkeltsammensetning som omfatter:

- a) en formulering med umiddelbar frigjøring av metylfenidat eller et farmasøytisk akseptabelt salt derav; og
- b) en forsinket og pulserende frigjøringsformulering av ondansetron eller et farmasøytisk akseptabelt salt derav;

for bruk i en metode for behandling av en stoffrelatert lidelse, hvori en in-vitro frigjøringsprofil av metylfenidatet eller det farmasøytisk akseptable saltet derav i formuleringen med umiddelbar frigjøring er en oppløsningshastighet større enn eller lik 80 % i mindre enn eller lik 1 time eller større enn eller lik 90 % i mindre enn eller lik 2 timer under simulerte testbetingelser for mage- eller tarmoppløsning, hvori en in-vitro frigjøringsprofil av ondansetronet eller farmasøytisk akseptabelt salt derav i formuleringen er den forsinkede og pulserende frigjøring en oppløsningshastighet på mindre enn eller lik 10 % i mer enn eller lik 3 timer og større enn eller lik 80 % i mindre enn eller lik 7 timer under simulerte testbetingelser for mage- eller tarmoppløsning, og hvori den stoffrelaterte lidelsen inkluderer psykostimulerende bruksforstyrrelse, tobakksbruksforstyrrelse, alkoholbruksforstyrrelse eller cannabisbruksforstyrrelse.

2. Enkeltsammensetningen for bruk ifølge krav 1, hvori metylfenidatet har en terminal halveringstid på mindre enn eller lik 5 timer og ondansetronet har en terminal halveringstid på 3 timer til 13 timer.